Current drug delivery最新文献

{"title":"Biocompatibility Evaluation of a Dexamethasone Mucoadhesive Nanosystem: Preclinical and Preliminary Clinical Evaluations.","authors":"Graciela Lizeth Perez-Gonzalez, Luis Jesus Villarreal-Gomez, Lucia Margarita Valenzuela Salas, Edgar Ramiro Mendez Sanchez, Jose Manuel Cornejo-Bravo","doi":"10.2174/0115672018356821250323083549","DOIUrl":"10.2174/0115672018356821250323083549","url":null,"abstract":"<p><strong>Introduction: </strong>There is a strong need for drug delivery systems that are both highly compatible with biological tissues and effective when used in the oral mucosa. While gels, creams, or ointments are currently employed for this purpose, their oral bioavailability is constrained by the limited contact time with mucosal tissue.</p><p><strong>Methods: </strong>In response to this challenge, we developed and evaluated the efficacy of a multilayer mucoadhesive system incorporated with Dexamethasone Sodium Phosphate (DEX-P) for oral mucosal delivery. An electrospun multilayer system was created and subjected to biocompatibility and efficacy testing via in vitro and ex vivo approaches, finally culminating in an acceptability trial in healthy human volunteers. The multilayer system was created using Poly-Vinyl Pyrrolidone (PVP) and Poly ε-Caprolactone (PCL) as a polymeric base and Polycarbophil (NOVEON® AA-1, PCF) serving as an adhesion enhancer to facilitate the unidirectional release of Dexamethasone Sodium Phosphate (DEX-P).</p><p><strong>Results: </strong>The nanofibers matrices underwent morphological characterization by Scanning Electron Microscopy (SEM), and DEX-P release was evaluated using ex vivo porcine mucosa, yielding promising results. In vitro cytotoxicity was evaluated through the MTT assay, employing HFF-1 cells. The cell viability ranged from 78 to 96%, suggesting the safety of the polymers used. The tested dose range of DEX on cell lines did not decrease below 75%, indicating its safety in terms of in vivo cytotoxicity. Biocompatibility was evaluated on animal models, without significant tissue damage observed.</p><p><strong>Discussion: </strong>The results of this study demonstrate the potential of the developed multilayer mucoadhesive system as an effective platform for oral mucosal drug delivery. The combination of PVP and PCL provides a stable and tunable matrix for drug incorporation, while PCF successfully enhances mucoadhesion and controlled drug release. The electrospun architecture enables precise drug loading and unidirectional release, which is crucial for minimizing systemic absorption and maximizing local therapeutic effects. The high cell viability observed in vitro and the absence of significant tissue damage in vivo underline the biocompatibility of the system. Moreover, the positive feedback from human volunteers not only indicates functional efficacy but also practical usability, which is essential for clinical translation. Taken together, these findings support the feasibility of using this multilayer nanofiber system as a safe and effective vehicle for oral mucosal therapy, particularly for localized delivery of corticosteroids, such as DEX-P.</p><p><strong>Conclusion: </strong>Human in vivo studies demonstrated prolonged adhesion and a favorable perception of the system.</p>","PeriodicalId":94287,"journal":{"name":"Current drug delivery","volume":" ","pages":"724-734"},"PeriodicalIF":3.0,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144040455","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Advances in Nanostructured Lipid Carriers for Colorectal Cancer Treatment: A Comprehensive Review.","authors":"Riya Patel, Shailvi Shah, Sheetal Acharya, Gayatri Patel, Shreeraj Shah, Bhupendra G Prajapati","doi":"10.2174/0115672018340391250321041056","DOIUrl":"10.2174/0115672018340391250321041056","url":null,"abstract":"<p><p>As colorectal cancer is the third most common cancer globally, this study aimed to improve colorectal cancer treatment using nanostructured lipid carriers (NLCs) for drug delivery by overcoming the current drawbacks, improving therapeutic effectiveness, achieving site-specific delivery, and implementing controlled drug administration to mitigate systemic side effects. Based on the literature, it has been observed that the optimal drug size and zeta potential range depend on the drug formulation's targets and features. These ranges are determined through optimization and characterization. The particle size ranges from 10 to 200 manometers, and the zeta potential values range from -30 mV to +30 mV. Optimal formulations should have uniform spherical morphology and compatibility with biological entities. This paper provides an in-depth analysis of nanocarrier research and findings. This article offers a thorough synopsis of the latest research and findings on nanocarriers, offering a valuable understanding of their development.</p>","PeriodicalId":94287,"journal":{"name":"Current drug delivery","volume":" ","pages":"648-669"},"PeriodicalIF":3.0,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144040416","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Exploring Drug Repositioning: Enhanced Co-Delivery of Disulfiram and Celecoxib by Nanostructured Lipid Carriers for Breast Cancer Cells.","authors":"Theodora Amanda Seidu, Muhammad Asim Farooq, Masanja Pius Wande, Sana Ghayas, Perpetua Takunda Kutoka, Raphael N Alolga, Bo Wang","doi":"10.2174/0115672018287555240426063812","DOIUrl":"10.2174/0115672018287555240426063812","url":null,"abstract":"<p><strong>Introduction: </strong>In the current era, the importance of pharmaceutical technology and research in innovating novel drugs and formulations is undeniable. This study aimed to produce a nanoscale drug delivery system for the simultaneous delivery of repurposed disulfiram (DSF) and celecoxib (CXB).</p><p><strong>Methods: </strong>The co-formulation was prepared utilizing the emulsification ultrasonication technique to enhance the anti-cancer activity through NLCs. The surface morphology of the optimized NLCs was examined using TEM, while physicochemical characterization analyses employed FTIR, DSC, PXRD, and TGA. In-vitro cell uptake studies were conducted through MTT assay, confocal microscopy, and flow cytometry, respectively.</p><p><strong>Results: </strong>The optimized DSF-CXB NLCs demonstrated a mean particle size of 144.2 nm, with a drug loading of 9.8% for DSF and 9.87% for CXB. The re-dispersibility index was measured at 103.26%, indicating effective dispersion. Stability analysis over 30 days confirmed the formulation's high stability. Transmission electron microscopy revealed spherical-shaped nanoparticles. Fourier transform infrared spectroscopy indicated no interaction between excipients and the formulation. Both DSC and PXRD techniques affirmed complete encapsulation of both drugs in the NLCs. In-vitro cytotoxicity of DSF-CXB NLCs exhibited a concentration-dependent increase compared to free DSF and CXB solutions in breast cancer cells. Confocal microscopy and flow cytometry studies demonstrated time-dependent internalization of the optimized formulation in 4T1 cancer cells.</p><p><strong>Conclusion: </strong>These results suggest that repurposing DSF and CXB NLCs holds promise as a co-delivery system for various cancers, potentially leading to improved therapeutic outcomes.</p>","PeriodicalId":94287,"journal":{"name":"Current drug delivery","volume":" ","pages":"876-893"},"PeriodicalIF":3.0,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144877689","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Brain Targeting Using Nanocolloids for the Management of Multiple Sclerosis.","authors":"Smita Jain, Kaisar Raza","doi":"10.2174/0115672018330624241125060045","DOIUrl":"10.2174/0115672018330624241125060045","url":null,"abstract":"<p><p>Multiple sclerosis (MS) causes sensory and motor deficiencies by breaking the myelin sheath, which inhibits electrical impulses from reaching affected neurons. The blood-brain barrier (BBB) and unanticipated side effects from inadequate targeting are major hurdles to MS treatment. Nanomedicines are being used to deliver therapeutic chemicals to lesions in order to address the limitations of existing MS therapy approaches. Nano-based therapies with deep BBB penetration and selective targeting have shown promising results, emerging as a possible therapy strategy for MS with improved therapeutic effects. This review will suggest the latest developments in nano-colloidsbased therapy for treating MS by evaluating their advantages and disadvantages.</p>","PeriodicalId":94287,"journal":{"name":"Current drug delivery","volume":" ","pages":"338-350"},"PeriodicalIF":3.0,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144334758","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Facile Synthesis of Monodisperse Gold Nanorods, Gold Nanobipyramids and Gold Nanocups with Different Coatings and Evaluation of Their Cellular Cytotoxicity.","authors":"Fanjiao Zuo, Shuting Zhou, Xiwei Wu, Boyao Wang, Jun He, Xilong Qiu","doi":"10.2174/0115672018337291241118045126","DOIUrl":"10.2174/0115672018337291241118045126","url":null,"abstract":"<p><strong>Introduction: </strong>Assessing the cytotoxicity of gold nanoparticles (GNPs) has gained importance due to their development in the biomedical field.</p><p><strong>Methods: </strong>In this study, we systematically synthesized gold nanorods (GNRs), gold nanobipyramids (GNBPs), and gold nanocups (GNCs) using a seed-mediated method, with an average length of 32.53 ± 4.67 nm, 72.90 ± 7.54 nm and 118.01 ± 11.02 nm, respectively.</p><p><strong>Results: </strong>Furthermore, using the cell counting kit-8 (CCK-8) assay, we assessed the cellular cytotoxicity of three different types of GNPs with various different surface coatings, such as organic cetyltrimethylammonium bromide (CTAB) and polyethylene glycol (PEG). The results showed that the cytotoxic behavior of GNPs was shape-dependent in the concentration range of 3.125 -100 µg/mL. The types of GNPs and their surface coating had a significant impact on how the GNPs behaved in cells. Compared to PEG-coated GNPs, which do not induce cell injury, CTAB-coated GNPs show more noticeable cytotoxicity.</p><p><strong>Conclusion: </strong>Furthermore, compared to GNCs, the toxicity of GNRs and GNBPs against GES-1 cells, RAW 264.7 cells and LX-2 cells was greater. Our research provides an important new understanding of the effects of surface modification on the biocompatibility and the shape of GNPs in the biomedical field.</p>","PeriodicalId":94287,"journal":{"name":"Current drug delivery","volume":" ","pages":"203-209"},"PeriodicalIF":3.0,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142980791","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Lactoferrin-Conjugated Nanocarriers for Transformative Strategies in Cancer Management: New Insights on Breast Cancer Therapy.","authors":"Rakesh Pahwa, Sanskriti Saini, Gulshan Sharma, Rohil Panwar, Hardeep Singh Tuli, Neeraj Mishra, Sukriti Vishwas, Thakur Gurjeet Singh, Gaurav Gupta, Harish Dureja, Sachin Kumar Singh","doi":"10.2174/0115672018351146250307083901","DOIUrl":"10.2174/0115672018351146250307083901","url":null,"abstract":"<p><p>Cancer represents a diverse and complex spectrum of diseases characterized by the abnormal growth and proliferation of cells, establishing a formidable global health challenge. Within the array of diverse cancers, breast cancer arises as one of the primary contributors to cancer-related fatalities in females. Breast cysts, thickenings, alterations in breast size or form, etc., are all prevalent and well-known signs of breast cancer. Despite remarkable progression in cancer research and the abundance of potent drugs, the effectiveness of conventional therapy is still hindered by various complications. In this avenue, nanocarriers present considerable promise for delivering therapeutics to cancerous cells, however, still numerous challenges persist in achieving successful targeted drug delivery and localization. Recent progress has emphasized the utilization of ligand-functionalized nanocarriers to enhance the delivery at target tissues and improve uptake by cancer cells. This approach contributes to increased accuracy and efficacy, which ultimately leads to enhanced patient outcomes. Lactoferrin, a multifunctional glycoprotein, is currently receiving significant attention as a promising ligand for targeted drug delivery in cancerous cells, especially breast cancer cells. This review provides new insight into ligand-targeted therapy, emphasizing the key benefits and notable features of utilizing lactoferrin as a targeting ligand for delivering drug-loaded nanocarriers to tumor sites.</p>","PeriodicalId":94287,"journal":{"name":"Current drug delivery","volume":" ","pages":"423-439"},"PeriodicalIF":3.0,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143723042","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Smart Nanofibers in Wound Healing: Exploring Novel Combinations and Applications.","authors":"Badriyah Shadid Alotaibi, Madiha Khan, Nihal Abdalla Ibrahim, Abida Kalsoom Khan, Rabia Liaqat, Munaza Ijaz","doi":"10.2174/0115672018376778250616113903","DOIUrl":"10.2174/0115672018376778250616113903","url":null,"abstract":"<p><p>Due to certain limitations of traditional therapies, millions of people all over the world suffering from chronic wounds are exploring new treatments. As single-layer nanofibers cannot meet different wound surface needs, multifunctional nanofibers with drug combinations surpass the limitation of conventional drug-polymer combinations. Traditional wound therapies have several limitations, prompting the search for more effective alternatives, particularly for chronic wounds. Singlelayer nanofibers often fail to meet diverse wound-healing needs, whereas multifunctional nanofibers, incorporating drug combinations, overcome these limitations. Polymers, widely used in nanofiber formulations, exhibit immunostimulatory, anti-inflammatory, and antimicrobial properties, enhancing the woundhealing process. However, due to a lack of certain biological properties, researchers have formed hybrid polymers, which are a combination of natural and synthetic polymers to meet wound healing requirements. Despite their advantages in biocompatibility and tunable mechanical properties, the clinical translation of polymer-based nanofibers faces challenges in regulatory approval and largescale production. Most studies are still limited to in vitro evaluations, and standardized in vivo models or human trials are necessary to validate their long-term efficacy. Additionally, to meet FDA and DRAP guidelines, these materials must undergo rigorous biodegradation and cytotoxicity assessments before clinical adoption. Owing to several bioactive components (e.g., vitamins, polyphenols) in structures of herbal extract, they have excellent anti-inflammatory, antimicrobial, and antioxidant properties. Nanofibrous scaffolds of herbal extracts are in prominence and can have a multi-target synergistic impact. Among several treatments for repairing wounds, growth factors have also been proven as an effective treatment for active healing. This review will provide the researchers with a holistic view of recently reported novel multifunctional nanofibers composed of different combinations of drugs, polymers, herbal extracts, growth factors, and biomolecules to promote wound healing. Although several multifunctional nanofibers have been prepared and shown excellent properties for wound healing therapy, still development of multifunctional nanofibers still needs to be focused on. In a nutshell, multifunctional nanofibers have become very famous in the wound healing process, and a better scale-up of these nanofibers in the coming era will result in commercialization, and products of these nanofibers will become more popular.</p>","PeriodicalId":94287,"journal":{"name":"Current drug delivery","volume":" ","pages":"497-518"},"PeriodicalIF":3.0,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144556364","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Metformin-Embedded Hydrogels: A Promising Approach for Accelerating Healing in Diabetic Ulcers.","authors":"Jiaru Zhou, Xiangmei Liu, Tianyu Tang, Jiawei Liang, Huashen He, Yingyao Luo, Yanhua Guo, Peining Li, Junfeng Ban, Yan Zhang","doi":"10.2174/0115672018384803250713182036","DOIUrl":"10.2174/0115672018384803250713182036","url":null,"abstract":"<p><strong>Introduction: </strong>Difficulty in wound healing is a significant worldwide clinical challenge with serious health consequences and even life-threatening consequences. We designed an acrylic hydrogel loaded with metformin and investigated its mechanism of action in promoting wound repair.</p><p><strong>Methods: </strong>In this study, we obtained self-assembled metformin hydrogels (SAMHs) delivery system using acrylic acid (AA) as matrix and ammonium persulfate (APS) as initiator, and evaluated the appearance, water vapor transmission rate, swelling properties, mechanical properties, and bioactivities of the SAMHs, and finally assessed the potential of the SAMHs for the treatment of chronic wounds in a diabetic rat wound model.</p><p><strong>Results: </strong>SAMHs were colorless and transparent in appearance, with a water vapor transmission rate of 3530 g·m^-2·day^-1, a dissolution rate of 504%, a Young's modulus of 34 Kpa, and an elongation at break of 595.7%.The drug loading capacity of SAMHs was 0.8±0.04 mg·g^-1 and the cumulative release amounted to 71.67.2.03%. In vivo experiments showed that on day 14, the SAMHs group achieved a wound healing rate of 96.74%, with complete epithelialization, a collagen fiber content of 75.10%, elevated VEGF expression, and a TNF-α level of 162.62 pg·mL-¹, all of which exhibited significant differences compared to the control group.</p><p><strong>Discussion: </strong>SAMHs exhibit excellent performance in several aspects, achieving slow drug release and promoting wound repair. In addition, SAMHs are simple and low-cost to prepare, which is expected to bring more cost-effective treatment options for diabetic patients. However, antimicrobial properties and clinical trial data are lacking in this study, and their applicability in complex wounds requires further validation.</p><p><strong>Conclusion: </strong>The hydrogel we prepared has excellent properties, is suitable for use in chronic wounds and promotes wound healing in diabetic rats and is an effective therapeutic strategy for chronic wounds.</p>","PeriodicalId":94287,"journal":{"name":"Current drug delivery","volume":" ","pages":"779-790"},"PeriodicalIF":3.0,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144746695","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Innovative Approaches in Drug Delivery Systems.","authors":"Yagmur Akdag, Tugba Gulsun","doi":"10.2174/0115672018520655260730100625","DOIUrl":"https://doi.org/10.2174/0115672018520655260730100625","url":null,"abstract":"","PeriodicalId":94287,"journal":{"name":"Current drug delivery","volume":"23 8","pages":"895-896"},"PeriodicalIF":3.0,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149303446","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Nanostructured Systems for Effective Transdermal Drug Delivery.","authors":"Renu Kadian","doi":"10.2174/0115672018355526250311045617","DOIUrl":"10.2174/0115672018355526250311045617","url":null,"abstract":"<p><strong>Introduction: </strong>One of the least invasive, recognized potential routes for both local and systemic drug delivery and the most patient-friendly methods of administering therapeutic agents is transdermal drug delivery. It minimizes gastrointestinal side effects, prevents hepatic first-pass metabolism, lowers dosage frequency, and boosts patient compliance.</p><p><strong>Objective: </strong>This review aims to examine the nanostructured systems for transdermal drug delivery, focusing on their types, design, development and mechanism in enhancing drug permeation through the skin.</p><p><strong>Methods: </strong>This review article synthesized findings from recent studies on nanostructured systems used in transdermal drug delivery systems. With a particular focus on offering a comprehensive understanding of transdermal drug delivery methods and augmentation strategies, the author examines current trends and potential uses of transdermal technologies.</p><p><strong>Results: </strong>Nanostructured systems have shown increased drug penetration, improved bioavailability and controlled release profiles.</p><p><strong>Conclusion: </strong>Nanostructured systems offer a versatile and effective approach to overcoming the limitations of traditional transdermal drug delivery methods. Future research should focus on optimizing these systems for clinical applications, ensuring safety and regulatory compliance.</p>","PeriodicalId":94287,"journal":{"name":"Current drug delivery","volume":" ","pages":"260-278"},"PeriodicalIF":3.0,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144791193","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}